[CAS NO. 1354825-58-3] WEHI-345
PRODUCTS SPECIFICATIONS [1354825-58-3]
DESCRIPTION [1354825-58-3]
Overview
| MDL | MFCD29472247 |
|---|---|
| Molecular Weight | 401.46 |
| Molecular Formula | C22H23N7O |
| SMILES | O=C(C1=CC=NC=C1)NCC(C)(N2N=C(C3=CC=C(C)C=C3)C4=C(N)N=CN=C42)C |
2 Publications Citing Use of MCE
Summary
IC50 & Target
IC 50 : 0.13 μM (RIPK2 kinase) [1]
In Vitro
WEHI-345 (500 nM; Raw 267.4 cells) is able to inhibit MDP-induced autophosphorylation activity of RIPK2 in cells
[1]
.
WEHI-345 (500 nM; 0 hour, 2 hours, 4 hours, 8 hours; BMDMs or THP-1 cells) potently blocks MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in bone marrow-derived macrophages (BMDMs). In THP-1 cells, WEHI-345 reduces mRNA levels of NF-kB targets such as TNF, IL-8, IL-1b and A20
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | Raw 267.4 cells |
| Concentration: | 500 nM |
| Incubation Time: | |
| Result: | Inhibited MDP-induced autophosphorylation activity of RIPK2 in cells. |
RT-PCR [1]
| Cell Line: | BMDMs or THP-1 cells |
| Concentration: | 500 nM |
| Incubation Time: | 0 hour, 2 hours, 4 hours, 8 hours |
| Result: | Blocked MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in BMDMs. And reduced mRNA levels of NF-kB targets in THP-1 cells. |
In Vivo
WEHI-345 (20 mg/kg; intraperitoneal injection; twice daily; for 6 days; C57BL/6 male mice) treatment reduces disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improves body weight and reduces cytokine and chemokine levels, indicating an overall improvement of the condition in experimental autoimmune encephalomyelitis (EAE)-induced wild-type C57Bl/6 mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6 male mice (8-week-old) [1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; twice daily; for 6 days |
| Result: | Reduced disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improved body weight and reduced cytokine and chemokine levels. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 62.27 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4909 mL | 12.4545 mL | 24.9091 mL |
| 5 mM | 0.4982 mL | 2.4909 mL | 4.9818 mL |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.4909 mL |